Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02133846 · ClinicalTrials.gov registry record · Phase 1
Safety Study of TPI-287 to Treat CBS and PSP
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT02133846 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 44 participants.
The verdict
NCT02133846, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability \[maximum tolerated dose (MTD) within planned dosing range\] of intravenous (IV) infusions of TPI 287 administered once every 3 weeks for 9 weeks (for a total of 4 infusions) in patients with primary four repeat tauopathies (4RT), corticobasal syndrome (CBS; also called corticobasal degeneration, CBD) or progressive supranuclear palsy (PSP).
Interventions
- DRUG Placebo
- DRUG TPI 287 2 mg/m2
- DRUG TPI-287 20 mg/m2
- DRUG TPI-287 6.3 mg/m2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2014-05 |
| Est. Completion | 2019-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02133846
The ClinicalTrials.gov registry entry for NCT02133846 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02133846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02133846 about?
NCT02133846 is a clinical study titled "Safety Study of TPI-287 to Treat CBS and PSP". The purpose of this study is to determine the safety and tolerability \[maximum tolerated dose (MTD) within planned dosing range\] of intravenous (IV) infusions of TPI 287 administered once every 3 weeks for 9 weeks (for a total of 4 infusions) in patients with primary four repeat tauopathies (4RT),...
What is the current status of trial NCT02133846?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2014-05. Estimated completion is 2019-09.
What interventions are being tested in trial NCT02133846?
The interventions under investigation include: Placebo (DRUG), TPI 287 2 mg/m2 (DRUG), TPI-287 20 mg/m2 (DRUG), TPI-287 6.3 mg/m2 (DRUG).
Who is sponsoring clinical trial NCT02133846?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.